Melittin suppresses cathepsin S-induced invasion and angiogenesis via blocking of the VEGF-A/VEGFR-2/MEK1/ERK1/2 pathway in human hepatocellular carcinoma

Oncology Letters

Volumn 11, Issue 1, 2016, Pages 610-618

  Zhang, Zhi ^a   Zhang, Hanguang ^a   Peng, Tao ^a   Li, Dongdong ^a   Xu, Jing ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Cathepsin S; Human hepatocellular carcinoma; Invasion; Melittin

Indexed keywords

CATHEPSIN S; MELITTIN; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLAT PLATE COLONY FORMATION ASSAY.; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; TRANSWELL MIGRATION ASSAY; WESTERN BLOTTING; WOUND HEALING MIGRATION ASSAY;

EID: 84948808569     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3957     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Lau WY and Lai EC: Hepatocellular carcinoma: Current management and recent advances. Hepatobiliary Pancreat Dis Int 7: 237-257, 2008.
3. Altekruse SF, McGlynn KA and Reichman ME: Hepatocellular carcinoma incidence, mortality and survival trends in the United States from 1975 to 2005. J Clin Oncol 27: 1485-1491, 2009.
4. Llovet JM: Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40: 225-235, 2005.
5. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
6. Sato M, Tateishi R, Yasunaga H, Horiguchi H, Yoshida H, Matsuda S and Koike K: Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: A national survey of 54,145 patients. J Gastroenterol 47: 1125-1133, 2012.
7. Xu ZY and Zheng Z: An optimized 3-step strategy for preventing and treating post-operation relapse and metastasis of malignant tumors with traditional Chinese medicine. Zhong Xi Yi Jie He Xue Bao 5: 5-10, 2007 (In Chinese).
8. Lu X, Zhao H, Yang H, Mao Y, Sang X, Miao R, Xu Y, Du S, Xu H, Chi T, et al: A prospective clinical study on early recurrence of hepatocellular carcinoma after hepatectomy. J Surg Oncol 100: 488-493, 2009.
9. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, et al: A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 187-196, 2004.
10. Bhowmick NA, Neilson EG and Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337, 2004.
11. Yang JD, Nakamura I and Roberts LR: The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets. Semin Cancer Biol 21: 35-43, 2011.
12. Spano D and Zollo M: Tumor microenvironment: A main actor in the metastasis process. Clin Exp Metastasis 29: 381-395, 2012.
13. Zhang L, Wang JN, Tang JM, Kong X, Yang JY, Zheng F, Guo LY, Huang YZ, Zhang L, Tian L, et al: VEGF is essential for the growth and migration of human hepatocellular carcinoma cells. Mol Biol Rep 39: 5085-5093, 2012.
14. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D and Joyce JA: Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20: 543-556, 2006.
15. Brömme D, Bonneau PR, Lachance P, Wiederanders B, Kirschke H, Peters C, Thomas DY, Storer AC and Vernet T: Functional expression of human cathepsin S in Saccharomyces cerevisiae. Purification and characterization of the recombinant enzyme. J Biol Chem 268: 4832-4838, 1993.
16. Levicar N, Strojnik T, Kos J, Dewey RA, Pilkington GJ and Lah TT: Lysosomal enzymes, cathepsins in brain tumour invasion. J Neurooncol 58: 21-32, 2002.
17. Wang B, Sun J, Kitamoto S, Yang M, Grubb A, Chapman HA, Kalluri R and Shi GP: Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 281: 6020-6029, 2006.
18. Xu J, Li D, Ke Z, Liu R, Maubach G and Zhuo L: Cathepsin S is aberrantly overexpressed in human hepatocellular carcinoma. Mol Med Rep 2: 713-718, 2009.
19. Sevenich L, Schurigt U, Sachse K, Gajda M, Werner F, Müller S, Vasiljeva O, Schwinde A, Klemm N, Deussing J, et al: Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci USA 107: 2497-2502, 2010.
20. Fernández PL, Farré X, Nadal A, Fernández E, Peiró N, Sloane BF, Shi GP, Chapman HA, Campo E and Cardesa A: Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer 95: 51-55, 2001.
21. Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin Oncol 29 (6 Suppl 16): 10-14, 2002.
22. Fan Q, Wang X, Zhang H, Li C, Fan J and Xu J: Silencing cathepsin S gene expression inhibits growth, invasion and angiogenesis of human hepatocellular carcinoma in vitro. Biochem Biophys Res Commun 425: 703-710, 2012.
23. Shibuya M: Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti-and Pro-Angiogenic Therapies. Genes Cancer 2: 1097-1105, 2011.
24. Roy H, Bhardwaj S and Ylä-Herttuala S: Biology of vascular endothelial growth factors. FEBS Lett 580: 2879-2887, 2006.
25. Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I and Philip PA: Vascular endothelial growth factor in the management of hepatocellular carcinoma: A review of literature. Cancer 115: 4895-4906, 2009.
26. Yen CJ, Lin YJ, Yen CS, Tsai HW, Tsai TF, Chang KY, Huang WC, Lin PW, Chiang CW and Chang TT: Hepatitis B virus X protein upregulates mTOR signaling through IKKbeta to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS One 7: e41931, 2012.
27. Waldner MJ and Neurath MF: Targeting the VEGF signaling pathway in cancer therapy. Expert Opin Ther Targets 16: 5-13, 2012.
28. Boman HG, Wade D, Boman IA, Wåhlin B and Merrifield RB: Antibacterial and antimalarial properties of peptides that are cecropin-melittin hybrids. FEBS Lett 259: 103-106, 1989.
29. Jang HS, Kim SK, Han JB, Ahn HJ, Bae H and Min BI: Effects of bee venom on the pro-inflammatory responses in RAW264.7 macrophage cell line. J Ethnopharmacol 99: 157-160, 2005.
30. Jo M, Park MH, Kollipara PS, An BJ, Song HS, Han SB, Kim JH, Song MJ and Hong JT: Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway. Toxicol Appl Pharmacol 258: 72-81, 2012.
31. Lee JD, Kim SY, Kim TW, Lee SH, Yang HI, Lee DI and Lee YH: Anti-inflammatory effect of bee venom on type II collagen-induced arthritis. Am J Chin Med 32: 361-367, 2004.
32. Park HJ, Lee HJ, Choi MS, Son DJ, Song HS, Song MJ, Lee JM, Han SB, Kim Y and Hong JT: JNK pathway is involved in the inhibition of inflammatory target gene expression and NF-kappaB activation by melittin. J Inflamm (Lond) 5: 7, 2008.
33. Chu ST, Cheng HH, Huang CJ, Chang HC, Chi CC, Su HH, Hsu SS, Wang JL, Chen IS, Liu SI, et al: Phospholipase A2-independent Ca2+ entry and subsequent apoptosis induced by melittin in human MG63 osteosarcoma cells. Life Sci 80: 364-369, 2007.
34. Li B, Gu W, Zhang C, Huang XQ, Han KQ and Ling CQ: Growth arrest and apoptosis of the human hepatocellular carcinoma cell line BEL-7402 induced by melittin. Onkologie 29: 367-371, 2006.
35. Liu S, Yu M, He Y, Xiao L, Wang F, Song C, Sun S, Ling C and Xu Z: Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology 47: 1964-1973, 2008.
36. Huh JE, Kang JW, Nam D, Baek YH, Choi DY, Park DS and Lee JD: Melittin suppresses VEGF-A-induced tumor growth by blocking VEGFR-2 and the COX-2-mediated MAPK signaling pathway. J Nat Prod 75: 1922-1929, 2012.
37. Gajski G and Garaj-Vrhovac V: Melittin: A lytic peptide with anticancer properties. Environ Toxicol Pharmacol 36: 697-705, 2013.
38. Shi GP, Sukhova GK, Kuzuya M, Ye Q, Du J, Zhang Y, Pan JH, Lu ML, Cheng XW, Iguchi A, et al: Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res 92: 493-500, 2003.
39. Lee TK, Cheung VC, Lu P, Lau EY, Ma S, Tang KH, Tong M, Lo J and Ng IO: Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 60: 179-191, 2014.
40. Hu H, Chen D, Li Y and Zhang X: Effect of polypeptides in bee venom on growth inhibition and apoptosis induction of the human hepatoma cell line SMMC-7721 in-vitro and Balb/c nude mice in-vivo. J Pharm Pharmacol 58: 83-89, 2006.
41. Yusuf N, Irby C, Katiyar SK and Elmets CA: Photoprotective effects of green tea polyphenols. Photodermatol Photoimmunol Photomed 23: 48-56, 2007.
42. Flannery T, Gibson D, Mirakhur M, McQuaid S, Greenan C, Trimble A, Walker B, McCormick D and Johnston PG: The clinical significance of cathepsin S expression in human astrocytomas. Am J Pathol 163: 175-182, 2003.
43. Mohamed MM and Sloane BF: Cysteine cathepsins: Multifunctional enzymes in cancer. Nat Rev Cancer 6: 764-775, 2006.
44. Quesada AR, Muñoz-Chápuli R and Medina MA: Anti-angiogenic drugs: From bench to clinical trials. Med Res Rev 26: 483-530, 2006.
45. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.
46. Song CC, Lu X, Cheng BB, Du J, Li B and Ling CQ: Effects of melittin on growth and angiogenesis of human hepatocellular carcinoma BEL-7402 cell xenografts in nude mice. Ai Zheng 26: 1315-1322, 2007 (In Chinese).
47. Huh JE, Lee EO, Kim MS, Kang KS, Kim CH, Cha BC, Surh YJ and Kim SH: Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: Roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways. Carcinogenesis 26: 1436-1445, 2005.
48. Toomey DP, Murphy JF and Conlon KC: COX-2, VEGF and tumour angiogenesis. Surgeon 7: 174-180, 2009.
49. Lu N, Gao Y, Ling Y, Chen Y, Yang Y, Gu HY, Qi Q, Liu W, Wang XT, You QD and Guo QL: Wogonin suppresses tumor growth in vivo and VEGF-induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR2. Life Sci 82: 956-963, 2008.
50. Huh JE, Baek YH, Lee MH, Choi DY, Park DS and Lee JD: Bee venom inhibits tumor angiogenesis and metastasis by inhibiting tyrosine phosphorylation of VEGFR-2 in LLC-tumor-bearing mice. Cancer Lett 292: 98-110, 2010.